The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW. In those with more nephrology visits in the proceeding 12 months, the odds of SGLT2 inhibitor prescription were lower. Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ... During a poster session at the American Society of Nephrology Kidney Week 2022, Thomas Mavrakanas, MD, MSc, and ... Previous studies have shown that the use of sodium glucose linked transporter inhibitors (SGLT-2i) in nontransplant ... Coronary Heart Disease Risk Factors and Serum Expression Analysis
... Editor's Note: This content was written by Amit Goyal, MD, a cardiology fellow at the Cleveland Clinic, and co-founder ... Donna Shu-Han Lin, MD, and colleagues at National Taiwan University Hospital, Taipei, Taiwan, conducted a meta-analysis ... Of the approximately one in 11 adults worldwide with diabetes, 90% have type 2 diabetes mellitus. Globally, the ... The manufacturers of Jardiance (empagliflozin) accounted that the FDA has granted FastTrack status to the drug for the ... Dapagliflozin appears safe and effective across different diuretic subgroups of heart failure patients, a new analysis ... This week's edition features some drug updates: one on SGLT-2 inhibitors in type 2 diabetic patients, and another on ... The 2019 Heart Failure Society of America Scientific Meeting (HFSA 2019) in Philadelphia has wrapped up. DocWire News ... A majority of patients with type 2 diabetes mellitus, atherosclerotic cardiovascular disease, and low density ... This week's edition includes some troubling findings for statins, good things happening with canagliflozin, a new add-on ... Semaglutide (OZEMPIC) taken weekly as an add-on therapy to sodium-glucose cotransporter-2 (SGLT-2) inhibitors was ... Canagliflozin, recently approved for the reduction of heart attack and stroke risk in type 2 diabetics with known ... Subodh Verma, MD, of St. Michael's Hospital and University of Toronto, talks with DocWire News about the EMPA-HEART ... Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on ...